Prof Andrew Doig PhD


Full contact details
View graph of relations


Alzheimer’s Disease Alzheimer’s Disease is caused by a small protein called beta-amyloid clumping together, becoming toxic and killing brain cells. We design and discover new drugs to reduce the toxicity of beta-amyloid, in collaboration with our spin-out company, Senexis. We are finding out how beta-amyloid kills cells by measuring how the levels of all the proteins inside a cell change when beta-amyloid is added. This will give new targets for future drugs and help with the diagnosis of Alzheimer’s Disease. Type 2 Diabetes Type 2 diabetes appears to be caused by the toxic amylin peptide killing the islets cells in the pancreas that make insulin. We are therefore also seeing how proteins in cells are affected by amylin. De-Immunising GFP Green Flurorescent Protein (GFP) is very widely used to report on when genes are switched on. Its use is hindered, however, by causing an unwanted immune response. We are therefore engineering GFP to remove its immunogenicity while maintaining its colour. Drug Target Proteins Drug discovery typically requires the identification of protein targets capable of eliciting a desired biological response. We are studying drug target proteins to identify properties that are desirable in human drug targets for different diseases.

Research Networks and Beacons

Biology, Medicine and Health (BMH) Domains

Education / academic qualifications

  • 1991 - Doctor of Philosophy, Thermodynamics of Peptide Association and Protein Folding, University of Cambridge

Related information


Research output: Contribution to journalArticlepeer-review

Research output: Contribution to journalArticlepeer-review

View all (82)